Other News To Note
• Acton Pharmaceuticals Inc., of Marlborough, Mass., completed a licensing agreement with Sanofi U.S., part of Paris-based Sanofi AS, for prescription Nasacort HFA (triamcinolone acetonide) nasal aerosol to treat nasal allergy symptoms. Acton assumes the exclusive U.S. rights to develop and market Nasacort HFA, an intranasal steroid formulated with a hydrofluoroalkane propellant and delivered as a dry mist in a volume-pressurized metered dose. Under the agreement, Sanofi retains all rights to Nasacort AQ.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST